Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease

Next Previous
Search
Trial Profile

Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitapivat (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ESTIMATE

Most Recent Events

  • 12 Dec 2023 Results of the safety and efficacy of treatment with mitapivat in patients with SCD from the 1-year fixed-dose extension period , presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 15 Jun 2023 Results (n=9) assessing pre-specified safety and efficacy data of the 1-year fixed-dose extension period (FDEP) ofmitapivat treatment in subjects with SCD, presented at the 28th Congress of the European Haematology Association.
  • 11 May 2023 According to an Agios Pharmaceuticals Media Release, data from this trial will be presented at the 2023 European Hematology Association (EHA) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top